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Retinal rod cGMP phosphodiesterase (PDE6 family) is
the effector enzyme in the vertebrate visual transduc-
tion cascade. Unlike other known PDEs that form cata-
lytic homodimers, the rod PDE6 catalytic core is a het-
erodimer composed of  and  subunits. A system for
efficient expression of rod PDE6 is not available. There-
fore, to elucidate the structural basis for specific dimer-
ization of rod PDE6, we constructed a series of chimeric
proteins between PDE6 and PDE5, which contain the
N-terminal GAFa/GAFb domains, or portions thereof, of
the rod enzyme. These chimeras were co-expressed in
Sf9 cells in various combinations as His-, myc-, or FLAG-
tagged proteins. Dimerization of chimeric PDEs was as-
sessed using gel filtration and sucrose gradient centrif-
ugation. The composition of formed dimeric enzymes
was analyzed with Western blotting and immunopre-
cipitation. Consistent with the selectivity of PDE6
dimerization in vivo, efficient heterodimerization was
observed between the GAF regions of PDE6 and PDE6
with no significant homodimerization. In addition,
PDE6 was able to form dimers with the cone PDE6
subunit. Furthermore, our analysis indicated that the
PDE6 GAFa domains contain major structural determi-
nants for the affinity and selectivity of dimerization of
PDE6 catalytic subunits. The key dimerization selectiv-
ity module of PDE6 has been localized to a small seg-
ment within the GAFa domains, PDE6-59–74/PDE6-
57–72. This study provides tools for the generation of the
homodimeric  and  enzymes that will allow us to
address the question of functional significance of the
unique heterodimerization of rod PDE6.
Photoreceptor rod and cone cGMP phosphodiesterases
(PDE6 1 family) are the effector enzymes in the vertebrate
visual transduction cascade. The cascade is initiated by photo-
excitation of the visual receptor rhodopsin and leads to hydrol-
ysis of intracellular cGMP by transducin-activated PDE6 (1, 2).
PDE6 enzymes belong to a large superfamily of phosphodies-
terases of cyclic nucleotides that are critical modulators of
cellular levels of cAMP and cGMP. Currently, eleven PDE
families have been identified in mammalian tissues based on
primary sequence, substrate selectivity, and regulation (3, 4).
Rod PDE6 is composed of two homologous catalytic - and
-subunits of similar size and two copies of an inhibitory -sub-
unit (1, 5–8). Cone PDE6 catalytic dimer is made up of two
identical PDE subunits (9). A cone-specific inhibitory P-
subunit is highly homologous to the rod P (10). The -subunit
associates with soluble rod and cone PDEs. It interacts with the
methylated prenylated C termini of PDE6 catalytic subunits
and regulates the enzyme attachment to the membrane (11).
The role of the PDE -subunit in phototransduction is not
well-defined, although it may modify the activity of the cascade
by uncoupling transducin and PDE (12).
PDE6 enzymes have catalytic domains of about 280 aa res-
idues in the C-terminal part of the molecule, which is highly
conserved among all known cyclic nucleotide phosphodiester-
ases (3, 4). The catalytic region of photoreceptor PDEs closely
resembles the catalytic site of cGMP binding, cGMP-specific
PDE (PDE5) (45–48% sequence identity) (13). Furthermore,
PDE6 and PDE5 share a strong substrate preference for cGMP
and have similar patterns of inhibition by competitive inhibi-
tors, including zaprinast, dipyridamole, and sildenafil (13–15).
In addition to the C-terminal catalytic domain, PDE6 contains
two N-terminal GAF domains (GAFa and GAFb). GAF domains
have been recognized as a large family of domain homologues
and named for their presence in cGMP-regulated PDEs, adeny-
lyl cyclases, and the E. coli protein Fh1A (16). Besides PDE6,
several other PDE families possess GAF domains, including
cGMP-stimulated PDE (PDE2), PDE5 (13, 17, 18), PDE10 (19),
and PDE11 (20). At least one of the two GAF domains in the
PDE2, PDE5, and PDE6 catalytic subunits serves as a site for
noncatalytic binding of cGMP. Noncatalytic cGMP binding to
GAF domains affects the catalytic properties of PDE2 and
PDE5 (21–24). In PDE6, noncatalytically bound cGMP appears
to enhance the affinity of the inhibitory interaction between P
and the catalytic core (25, 26). The second major function of the
GAF domains is their role in dimerization of the PDE catalytic
subunits. Earlier biochemical studies of PDE2 and PDE5 indi-
cated that their dimerization occurs within the N-terminal
parts of the molecules (18, 27). Ultimate evidence on the inter-
subunit interface of PDE2 has been recently provided by a
solution of the crystal structure of PDE2A GAFa-GAFb do-
mains (28). The crystal structure revealed that the PDE2A
regulatory region forms a dimer with the interface formed by
the two GAFa domains (28). The role of PDE6 GAF domains in
dimerization is supported by recent electron microscopy imag-
ing of rod PDE6 (29). The imaging showed that the main
intersubunit interaction occurs between the very N-terminal
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domains, presumably involving GAFa modules, and indicated
that the GAFb domains may also contribute to the interface.
Almost all PDEs known to date are dimeric. However, the
role of dimerization in enzyme function is not understood.
Dimerization is not required for catalytic activity, because the
isolated monomeric catalytic domain of PDE5 (30) and the
monomeric short splice variant PDE4D2 (31) have been shown
to be catalytically active. Furthermore, a majority of PDEs,
with a notable exception of rod PDE6, form catalytic ho-
modimers (3, 4). Although the possibility of minor homodimeric
species,  and , has not been ruled out, the dominant
catalytic species of rod PDE6 is clearly a heterodimer  (32,
33). The functional significance of heterodimerization of rod
PDE remains unclear. It is as yet unknown if the catalytic
characteristics of PDE6 and PDE6 in the dimer are equiva-
lent. To circumvent the problem of a lack of efficient expression
of PDE6 in various cell types (34, 35), we have previously
developed a robust system for expression of PDE6/PDE5
chimeras in insect cells (36). In this study, we extended this
approach to chimeras between PDE6 and PDE5 to investi-
gate the structural basis for specific dimerization of the rod
PDE6 catalytic subunits. A series of chimeric proteins between
PDE6 and PDE5 have been constructed that contain the GAFa
and/or GAFb domains of PDE6 or PDE5. These chimeras were
expressed in Sf9 cells in various combinations as His-, myc-, or
FLAG-tagged proteins. The dimerization of chimeric PDE6
subunits was assessed using gel filtration, sucrose gradient
centrifugation, Western blotting, and immunoprecipitation
with anti-FLAG- and anti-myc-specific antibodies. The pat-
terns of dimerization of chimeric PDE6/PDE5 subunits are
consistent with the selectivity of PDE6 dimerization in rod
photoreceptor cells. Our results indicate that the PDE6 GAFa
domains contain major structural determinants for the affinity
and selectivity of dimerization of PDE6 catalytic subunits.
EXPERIMENTAL PROCEDURES
Materials—cGMP was obtained from Roche Molecular Biochemicals.
[3H]cGMP was a product of Amersham Biosciences. All restriction en-
zymes were purchased from New England BioLabs. AmpliTaq DNA
polymerase was a product of PerkinElmer Life Sciences, and Pfu DNA
polymerase was a product of Stratagene. All other reagents were pur-
chased from Sigma. Bovine holo-PDE6 was extracted from bleached rod
outer segment membranes and purified as described previously (33).
Cloning, Expression, and Purification of PDE6/PDE5 Chimeras—To
construct PDE6/PDE5 chimera FLAG---5 (see Fig. 1), the FLAG tag
DNA sequence was first inserted into the pFastBacHTb vector (Invitro-
gen) replacing the His6 sequence. A DNA fragment was PCR-amplified
using pFastBacHTb as a template, a 5-primer containing an RsrII site
and the FLAG tag sequence, and a 3-primer containing a BamHI site.
This fragment was then ligated with the large RsrII/BamHI fragment of
pFastBacHTb to produce pFastBacFLAG. A bovine retinal cDNA li-
brary kindly provided by Dr. W. Baehr (University of Utah) was used as
a template for PCR amplifications of PDE6 sequences. DNA coding
for PDE6-1–443 was PCR-amplified using primers carrying BamHI
and HindIII sites. DNA coding for PDE5–506-865 amino acids was
PCR-amplified using the pFastBacHTb-PDE5 template (36) and prim-
ers with the HindIII and XhoI sites. The two PCR products were ligated
into the pFastBacFLAG vector using the BamHI and XhoI sites. The
myc tag DNA sequence was inserted into the pFastBacHTb vector using
a PCR-directed cloning procedure similar to the insertion of the FLAG
tag sequence. The construct for chimera myc---5 (see Fig. 1) was
generated by ligation of the PCR-amplified PDE6-1–441 and PDE5–
506-865 DNAs into the BamHI and XhoI sites of pFastBacmyc.
The His-tagged PDE6/PDE5 chimeras were constructed by ampli-
fying appropriate regions of the PDE6 subunits with primers con-
taining unique restriction sites. When unique restriction sites were not
available at the desired location, first-round PCR products coding chi-
meric junctions were extended to the nearest unique sites in a second-
round PCR amplification. To improve the recognition of the His6 tag by
commercial antibodies, the His6 flanking sequence in the original
pFastBacHTb vector was replaced by the His6 flanking sequence from
pET-15b (Novagen). The DNA sequences of all constructs were con-
firmed by automated DNA sequencing at the University of Iowa DNA
core facility.
Generation of the recombinant bacmids, transfection of Sf9 cells, and
viral amplifications were carried out according to the manufacturer’s
recommendations (Invitrogen). For protein expression, Sf9 cell cultures
(10 ml, 2  106 cells/ml) were infected with one or two different viruses
at a multiplicity of infection of 3–10. Sf9 cells were harvested at 48 h
after infection by centrifugation and stored at 80 °C until use. Sf9
cells were resuspended in 3 ml of 20 mM Tris-HCl buffer (pH 8.0)
containing 2 mM MgSO4 and Complete
TM Mini protease inhibitor mix-
ture (one-third tablet) (Roche Molecular Biochemicals) and sonicated
with two 10-s pulses using a microtip attached to a 550 Sonic Dismem-
brator (Fisher Scientific). Sf9 cell lysates were cleared by centrifugation
(100,000  g, 90 min, 2 °C), dialyzed against 30 mM Tris-HCl buffer (pH
8.0) containing 130 mM NaCl, 2 mM MgSO4, and 50% glycerin, and then
centrifuged again at 100,000  g for 1 h at 2 °C. Dialysis against 50%
glycerin allowed a concentration of PDE samples by 4-fold and sub-
sequent storage at 20 °C without freezing. The presence of glycerin
did not affect the behavior of PDEs in gel filtration.
Gel Filtration and Fraction Analysis—Aliquots of dialyzed PDE sam-
ples (50–200 l) were injected into a Superose 12 10/30 column (Am-
ersham Biosciences) equilibrated at 25 °C with 30 mM Tris-HCl buffer
(pH 8.0) containing 100 mM NaCl and 2 mM MgSO4. Proteins were
eluted at 0.4 ml/min, and 0.4-ml fractions were collected starting at 17
min post-injection. Each fraction was assayed for PDE activity, protein
concentration, and the presence of chimeric PDEs by Western blotting.
PDE activity was measured using 10- to 20-l aliquots from fractions
and 5 M [3H]cGMP as described previously (37, 38). Protein concen-
trations were determined by the method of Bradford using IgG as a
standard (39). The column was calibrated with the following protein
standards: bovine thyroglobulin (670 kDa, 85 Å), horse ferritin (440
kDa, 61 Å), sweet potato -amylase (200 kDa), rabbit aldolase (158 kDa,
48.1 Å), bovine serum albumin (67 kDa, 35.5 Å), and chicken ovalbumin
(45 kDa, 30.5 Å). The Stokes radii for PDEs were estimated using the
correlation of elution volume with the Stokes radius proposed by Porath
(40). Gel filtration analyses were performed two or more times with
similar results for each PDE chimera combination from at least two
different preparations of Sf9 cell extracts. Results of a typical analysis
are shown.
Western blot analysis of the gel filtration fractions (20-l aliquots)
was performed following SDS-PAGE in 10% gels (41). Monoclonal anti-
polyhistidine, M2 monoclonal anti-FLAG, and monoclonal anti-c-myc
(clone 9E10) antibodies (Sigma) with the respective dilutions of 1:1500,
1:5000, and 1:5000 were utilized. The antibodyantigen complexes were
detected using anti-mouse antibodies conjugated to horseradish perox-
idase (Sigma) and ECL reagent (Amersham Biosciences). The composi-
tions of PDE complexes in fractions corresponding to dimeric enzymes
were examined by immunoprecipitation (IP). Aliquots of the gel filtra-
tion fractions (80 l) were incubated with or without anti-FLAG or
myc-antibodies (1 l) for 30 min at 25 °C followed by the addition of 5 l
of protein G-Agarose (Sigma) and incubation for 40 min at 25 °C. The
agarose beads were washed four times with 300 l of phosphate-buff-
ered saline (pH 7.1), and the bound proteins were eluted with an
SDS-PAGE sample buffer. PDE complexes were separated on 10% gels
and analyzed by Western blotting using appropriate antibodies.
Sucrose Gradient Centrifugation—Sucrose density gradients (5–
35%) were prepared in 30 mM Tris-HCl (pH 8.0) buffer containing 100
mM NaCl, 2 mM MgSO4, and 4 mM 2-mercaptoethanol using a Gradi-
Frac gradient former (Amersham Biosciences). Protein standards or
aliquots of 200 l from peak PDE gel filtration fractions were loaded
onto the gradients in 14-  89-mm centrifugation tubes and centrifuged
for 24 h at 40,000 rpm in a Beckman SW41 rotor at 4 °C. Fractions of
300 l were collected starting from the bottom of the tubes. Fractions
from the tubes with protein standards were analyzed for protein con-
centration, whereas fractions from the tubes containing PDE samples
were analyzed for PDE activity. Sucrose density centrifugations were
performed two times with similar results for each PDE preparation.
Results of a typical analysis are shown. The protein standards were:
bovine liver catalase (250 kDa, 11.3 S), rabbit aldolase (158 kDa, 7.3 S),
bovine serum albumin (67 kDa, 4.6 S), and chicken ovalbumin (45 kDa,
3.5 S). Sedimentation coefficients (s20,w) for chimeric PDEs were esti-
mated using a linear plot of distances traveled by standards from
meniscus versus the s20,w values of standards (42). The molecular
weights of PDEs were calculated using the estimated sedimentation
coefficients, the Stokes radii obtained from the gel filtration data, and
the following equation (43),
M s  NA 6   r/1	 v  
) (Eq. 1)
Selectivity of Dimerization of the PDE6 GAF Domains 10595
 at R









where s is the sedimentation coefficient; NA is Avogardo’s number;  is
the viscosity of the medium (0.01 gcm1s1), r is the Stokes radius; v
is the partial specific volume of a protein (0.73 cm3g1), and 
 is the
density of the medium (1 gcm3).
RESULTS
Selectivity of Dimerization of the GAFa-GAFb Domains of
Rod PDE6—Dimerization of PDE6 catalytic subunits is very
tight, and, apparently, there is no exchange of subunits be-
tween dimers once they are formed following the synthesis and
folding of the polypeptide chains. The dimer formation between
chimeric PDE6/PDE5 subunits was therefore assessed follow-
ing co-expression of these chimeras in Sf9 cells. Chimeric PDEs
(Fig. 1) from soluble fractions of Sf9 cells as well as native
PDE6 and recombinant wild-type PDE5 were examined by
FPLC gel filtration on a calibrated Superose 12 HR 10/30
column and by sucrose gradient centrifugation. The elution
profiles of native PDE6 and recombinant wild-type PDE5 on
the gel filtration column were very similar and corresponded to
an apparent molecular mass of 210 kDa (Fig. 2A), which is
consistent with dimerization of the catalytic subunits. Molecu-
lar masses of rod holoPDE6 (PDE2) and the PDE5 dimer
calculated from the sequences were 217 and 197 kDa, respec-
tively. Only relatively small fractions of the enzymes (15%
PDE5 and 10% PDE6) migrated as aggregates with high
molecular mass. The previously developed chimeric PDE, Chi4
(termed hereafter His---5), containing the cone PDE6
GAFa-GAFb region and the catalytic domain of PDE5 (36), is
predicted to form homodimers. The chromatographic behavior
of His---5 on a Superose 12 HR 10/30 column indicated an
apparent molecular mass of 200 kDa (Fig. 2A), which is in
good agreement with the theoretical molecular mass of 183 kDa
for the --5 homodimer. The fraction of aggregates in the
chimeric PDE (10%) was similar to those in PDE5 and PDE6
preparations.
We first constructed PDE6/PDE5 chimeras containing both
the GAFa and GAFb domains from either rod PDE6 (--5) or
PDE6 (--5) and the catalytic domain from PDE5 (Fig. 1). As
generally defined by the PDE sequence alignment and the
crystal structure (17, 28), the boundaries of the GAFa domains
are PDE6-54–220 and PDE6-52–218, and the boundaries of
the GAFb domains are PDE6-255–443 and PDE6-253–441.
The nonconserved N termini, PDE6-1–53 in --5 and
PDE6-1–51 in --5, were from the respective catalytic sub-
units. Chimera --5 was constructed for expression as a
FLAG-tagged protein, whereas --5 was generated as a myc-
tagged polypeptide. Gel filtration fractions were analyzed by
Western blotting for the presence of chimeric PDE proteins and
for PDE activity with cGMP as the substrate. Individual ex-
pression of FLAG---5 or myc---5 resulted in the formation
of only high molecular weight aggregates that migrated with
the exclusion volume of the Superose 12 column (Fig. 2, B and
FIG. 1. Schematic representation of PDE6/PDE5 chimeras.
Constructs are designated as follows: name of tag, composition of GAFa
domain, composition of GAFb domain, catalytic domain. Subscripts a
and  indicate replacements PDE6-59–74 and PDE6-57–72 within
the PDE6 and PDE6 GAF regions, respectively.
FIG. 2. Gel filtration profiles of PDE5, PDE6, and chimeric
PDEs --5, --5, and --5. A, rod holoPDE6 (50 g) (smaller
dashed line) mixed with the dialyzed cell extract of noninfected Sf9 cells
(100 l) or dialyzed cell extracts of Sf9 cells (100,000  g, 90 min)
infected with viruses for expression of PDE5 (50 l) (solid line) and
--5 (100 l) (larger dashed line) were subjected to FPLC gel filtra-
tion on a Superose 12 10/30 column (Amersham Biosciences). Frac-
tions of 0.4 ml were collected and analyzed for PDE activity. B and C,
chimeras FLAG---5 (B) and myc---5 (C) were expressed individu-
ally in Sf9 cells and the dialyzed soluble cell extracts (100,000  g, 90
min) were subjected to FPLC gel filtration. Fractions of 0.4 ml were
collected and analyzed for protein concentration (dashed line), PDE
activity (solid line), and by Western blotting with anti-FLAG or anti-
myc antibodies.
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C). Furthermore, the aggregates also migrated with the exclu-
sion volume on a Superose 6 HR 10/30 column (not shown),
which is capable of separating proteins weighing up to 1  106
kDa. Notably, these aggregates were capable of hydrolyzing
cGMP. When FLAG---5 and myc---5 were co-expressed in
Sf9 cells, a peak of PDE activity appeared in the fractions
corresponding to dimeric PDE species with an apparent molec-
ular mass of 200 kDa (Fig. 3A). Approximately 50% of the
total soluble FLAG/myc-tagged protein formed the dimeric en-
zyme. In the peak activity fractions 11 and 12, the enzyme
hydrolyzed cGMP with a Km value of 3.8 M and a Vmax of 21
nmol/min/mg of protein. The Western blot analysis of these
fractions using anti-FLAG and anti-myc antibodies confirmed
the presence of both FLAG---5 and myc---5 (Fig. 3A). A
sizable peak of PDE activity was also present in fractions
corresponding to aggregates of FLAG---5 and myc---5 (Fig.
3A). The aggregation appears to be irreversible, because re-
chromatography of the fractions with aggregates did not gen-
erate dimeric enzymes (not shown). Considering the intensity
of immunostaining, the catalytic activity of these aggregated
PDE species is 1.5- to 2-fold lower than that of the dimeric PDE
species.
To verify the nature of the dimeric species, chimeric PDE
was immunoprecipitated with anti-FLAG antibodies and then
probed with anti-myc antibodies using Western blotting. The
results of the IP experiments proved the formation of a het-
erodimer between FLAG---5 or myc---5 (Fig. 3A). The
peak of dimeric PDE activity on the gel filtration column was
relatively broad. To determine if this PDE might be heteroge-
neous, the combined concentrated front fractions 9–11 and tail
fractions 13–16 were reapplied onto the column. The resulting
PDE activity profiles were nearly identical, suggesting the
presence of a single dimeric form of PDE and trace amounts of
aggregates (Fig. 3B).
The molecular shape of a protein significantly influences its
migration on a gel filtration column. Sucrose density centrifu-
gation was utilized as an additional independent approach to
estimate the molecular weight of chimeric PDEs (42). The
sedimentation rates of native rod holoPDE6, recombinant
PDE5, His---5, and the FLAG---5myc---5 complex
were similar (Fig. 3C). An estimated s20,w value of 8.1 for the
FLAG---5myc---5 complex corresponds well to the dimeric
structure. Using this sedimentation coefficient and the Stokes
radius of 52 Å derived from the gel filtration data (Fig. 3A) (40),
Equation 1 (43) yields a molecular mass of 176 kDa, which is
comparable to the theoretical molecular mass (184 kDa) for the
FLAG---5myc---5 dimer.
Next, we examined the possibility of dimerization of PDE6
and PDE6 with cone PDE6 and PDE5. FLAG---5 and
myc---5 each were co-expressed with His---5 or His-
PDE5. Because PDE6 and PDE5 form catalytic homodimers,
a peak of PDE activity in gel filtration fractions corresponding
to dimeric PDE species cannot be used as evidence for het-
erodimerization. Instead, we relied on Western blot analysis of
FIG. 3. Analysis of dimerization of PDE chimeras --5 and
--5. A, chimeras FLAG---5 and myc---5 were co-expressed in Sf9
cells and examined by gel filtration on the Superose 12 column. Frac-
tions of 0.4 ml were collected and analyzed for protein concentration
(dashed line), PDE activity (solid line), and by Western blotting with
anti-FLAG or anti-myc antibodies. IP, an aliquot (80 l) of the dimeric
PDE peak fraction 12 was incubated with () or without () anti-FLAG
antibodies. Proteinantibody complexes were isolated using protein G-
agarose and analyzed by Western blotting with anti-myc as described
under “Experimental Procedures.” B, combined PDE peak front frac-
tions 9–11 (solid line) and tail fractions 13–16 (dashed line) were
concentrated by dialysis against 30 mM Tris-HCl buffer (pH 8.0) con-
taining 130 mM NaCl, 2 mM MgSO4, and 50% glycerin and then reap-
plied onto the column. C, combined peak PDE gel filtration fractions
10–13 were concentrated to a volume of 200 l using the YM-10 Micro-
con devices (Millipore Corp., Bedford, MA) and loaded onto the 5–35%
sucrose density gradients. Following centrifugation for 24 h at 40,000
rpm in a Beckman SW41 rotor, fractions of 300 l were collected
starting from the bottom of the tubes and analyzed for PDE activity.
Arrows indicate sedimentation of protein standards. PDE5, holoPDE6,
and --5 migrated at the same position of the gradient indicated as
PDE*.
FIG. 4. Analysis of dimerization of PDE chimeras --5 and
--5 with --5. His---5 was co-expressed with FLAG---5 (A)
or myc---5 (B) in Sf9 cells. Soluble Sf9 cell extracts (100,000  g, 90
min) were applied onto a FPLC Superose 12 10/30 gel filtration col-
umn. Aliquots (20 l) from 0.4-ml gel filtration fractions were analyzed
by Western blotting with anti-His, anti-FLAG, or anti-myc antibodies.
IP, an aliquot (80 l) of the dimeric FLAG---5His---5 peak frac-
tion 12 was incubated with () or without () anti-FLAG antibodies.
Proteinantibody complexes were isolated using protein G-agarose and
analyzed by Western blotting with anti-His as described under “Exper-
imental Procedures.”
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the fractions for the presence of FLAG---5 and myc---5.
The Western blot analysis of the gel filtration fractions of PDE
species formed upon co-expression of FLAG---5 and His--
-5 indicated heterodimerization between the two subunits
(Fig. 4A). The FLAG---5 signal appeared in fractions 10–14
corresponding to dimeric PDE. The immunoprecipitates of
these fractions with anti-FLAG antibodies contained His--
-5, demonstrating the heterodimeric composition of the
dimers (Fig. 4A). Co-expression of myc---5 and His---5
has not led to any significant dimer formation between the two
chimeric PDEs (Fig. 4B). Similarly, co-expression of FLAG--
-5 or myc---5 with PDE5 and examination of formed PDE
species revealed no detectable dimerization between the GAF
regions of rod PDE6 and PDE5 (not shown). The patterns of
dimerization --5 or --5 were consistent with the selectivity
of PDE6 dimerization in rod photoreceptor cells, allowing us to
use them as templates to further probe the role of the PDE6
GAFa and GAFb domains.
Roles of the GAFa and GAFb Domains in Rod PDE6 Dimer-
ization—To determine the contributions of the rod PDE6 GAFa
and GAFb domains to the enzyme dimerization, two new
PDE6/PDE5 chimeras have been constructed. Chimera His--
-5 contained the GAFa and GAFb domains from PDE6 and
PDE6, respectively (Fig. 1). The GAF domains were swapped
in the second chimera, His---5. If the rod PDE6 catalytic
subunits associate in a symmetrical “head-to-tail” fashion, His-
--5 and His---5 might have been capable of self-dimeriza-
tion. However, the gel filtration and Western blot analyses of
His---5 and His---5 expressed individually in Sf9 cells
revealed no formation of dimeric PDEs (not shown). In con-
trast, catalytically active dimeric PDE species were observed
following co-expression of His---5 and His---5 (not shown),
suggesting a “head-to-head” dimerization of the PDE6 and
PDE6 subunits. The lack of self-dimerization of FLAG---5,
myc---5, His---5, and His---5 allowed us to probe the
role of the GAFa and GAFb domains by co-expressing His---5
and His---5 with either FLAG---5 or myc---5. Two of the
four combinations, FLAG---5His---5 and myc---5His--
-5, yielded no dimeric PDE species (not shown). The other two
FIG. 5. Dimerization of --5 with --5 and --5 with --5. A
and B, combinations of chimeras, FLAG---5His---5 (A) and myc-
--5His---5 (B), were co-expressed in Sf9 cells and analyzed by
FPLC gel filtration on a Superose 12 10/30 column (dashed line,
protein concentration; solid line, PDE activity) and Western blotting
using anti-His, anti-FLAG, or anti-myc antibodies as described under
“Experimental Procedures.” C, combined peak FLAG---5His---5
(dashed line) and myc---5His---5 (solid line) gel filtration fractions
10–13 were concentrated to a volume of 200 l using the YM-10 Micro-
con devices (Millipore Corp., Bedford, MA) and loaded onto the 5–35%
sucrose density gradients. Following centrifugation for 24 h at 40,000
rpm in a Beckman SW41 rotor, fractions of 300 l were collected
starting from the bottom of the tubes and analyzed for PDE activity.
FIG. 6. Dimerization of --5 with -5–5, --5, or --5. Chi-
mera FLAG---5 was co-expressed with His--5–5 (A), His---5 (B),
or His---5 (D) in Sf9 cells. Chimera His---5 alone was expressed
in Sf9 cells to test its capacity for homodimerization (C). Dimer forma-
tion was examined by the Western blot analysis of the fractions follow-
ing separation of the chimeric PDEs on a Superose 12 10/30 column.
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combinations, FLAG---5His---5 and myc---5His---5,
produced functional dimeric enzymes as evidenced from the gel
filtration and sucrose density centrifugation data (Fig. 5). The
migrations of FLAG---5His---5 and myc---5His---5
in gel filtration and in the sucrose density gradient were sim-
ilar to those of the FLAG---5myc---5 complex. The cata-
lytic characteristics of FLAG---5His---5 (Km  2.7 M,
Vmax  20 nmol/min/mg) and myc---5His---5 (Km  4.9
M, Vmax  17 nmol/min/mg) assayed in the peak fractions #11
(Fig. 5, A and B) were comparable to those of FLAG---5myc-
--5. The results of these experiments suggest that the main
selectivity determinants of dimerization of PDE6 and PDE6
reside within the GAFa domains.
The GAFb domains of PDE6 and PDE6 are more homolo-
gous than the GAFa domains and may contribute to the affinity
of dimerization without influencing its selectivity. Chimera
His--5–5 containing the GAFa domain of PDE6 and the
GAFb domain of PDE5 was generated to test this possibility.
His--5–5 did not exhibit any propensity for self-dimerization
(not shown) but was able to efficiently form heterodimers with
FLAG---5 when the two proteins were co-expressed in Sf9
cells (Fig. 6A). Sucrose density centrifugation of FLAG---
5His--5–5 produced a s20,w value of 8.1 confirming the dimeric
nature of the complex (not shown). Therefore, the GAFb do-
mains of PDE6 do not significantly contribute to the dimeric
interface.
Mapping Dimerization Selectivity Determinants within the
GAFa Domains of PDE6—The dimerization properties of His-
--5 and His---5 indicated that the major selectivity deter-
minants are localized within PDE6-1–235 (PDE6-1–233).
Approximately 45-residue-long N-terminal sequences of the
PDE6 , , and  subunits are very dissimilar and are followed
by modestly conserved N-terminal portions of the GAFa do-
mains (aa 45–90). The degree of conservation between the
GAFa domains is higher in the remaining GAFa segments
(aa 90–230). This was taken into consideration in designing
chimeras His---5 and His---5 (Fig. 1). His---5 and
His---5 included the PDE6 sequences 1–93 and 94–235,
respectively, substituting corresponding sequences of PDE6.
After His---5 and His---5 showed no capacity for self-
dimerization, these chimeras were co-expressed with FLAG--
-5 or myc---5. The combinations FLAG---5His---5,
myc---5His---5, or myc---5His---5 produced no di-
meric PDE species as judged by the gel filtration and Western
blot analysis (not shown). On the contrary, His---5 and
FLAG---5 were capable of assembly of catalytically active
dimeric PDE (Fig. 6B). Sedimentation of FLAG---5His--
-5 in the sucrose gradient (s20,w 8.1) and the Km value for
FIG. 7. A model of the PDE6GAFa-PDE6GAFa dimer. A, a homology model of the PDE6GAFa-PDE6GAFa dimer was generated with
Swiss-PdbViewer (version 3.7b2) and SWISS-MODEL (44) using the coordinates of the PDE2A GAFa-GAFb dimer as a template (28). The image
was produced using Sybyl (version 6.6, Tripos). The PDE6GAFa and PDE6GAFa domains are shown in green and red, respectively. Putative
intersubunit contact regions PDE6-59–74 (white), PDE6-216–224 (cyan), PDE6-57–72 (yellow), and PDE6-214–222 (blue) are indicated by
arrows. B, sequence alignments (45) of the PDE6 , ,  and PDE2 segments corresponding to PDE6-59–74 and PDE6-216–224. PDE2
intersubunit contact residues within PDE2–220-235 are underlined. C, from the model, PDE6-59–74 (white) interacts with PDE6-57–72 (yellow)
and PDE6-214–222 (blue), and PDE6-57–72 interacts with PDE6-59–74 and PDE6-216–224 (cyan). D, schematic depiction of probable
interaction defects excluding homodimerization of PDE6 and PDE6.
TABLE I
Summary of dimerization properties of PDE6/PDE5 chimeras
See Fig. 1 for composition of the PDE chimeras.
Combinations of chimeras
forming dimeric PDEsa
Combinations of chimeras unable to form
dimeric PDEs




--5/--5 (2.7) --5/-5-5; --5/5--5; --5/5--5
--5/--5 (4.9) --5/--5; --5/--5
--5/-5-5 (2.3) --5/--5; --5/--5
--5/--5 (4.5)
--5/--5--5/--5 (4.2)
--5/--5 (ND) --5/--5; --5/--5
--5/--5 (3.4)
a Except for --5 and --5, all constructed PDE chimeras did not
form homodimeric species.
b Km values (M); ND, Km values are not determined due to ho-
modimerization of --5 or --5.
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cGMP hydrolysis (4.5 M) were equivalent to the properties of
other chimeric PDEs. In addition, His---5 formed dimers
with His---5 (not shown). These data indicate that at least
some PDE6 dimerization selectivity determinants are local-
ized to within 90 N-terminal residues of the PDE6  and 
subunits.
The major role of the GAFa domains in the dimerization of
both PDE2 (28) and PDE6 suggests similar topographies of the
intersubunit interfaces. The structure of the PDE2 (GAFa-
GAFb)2 dimer shows two main sites in each monomer that
participate in the intersubunit interface, one comprising a por-
tion of the -helix 1 and the 1/2 loop, and the second includ-
ing the helix connecting GAFa and GAFb (28). On the basis of
a homology model of the PDE6GAFa-PDE6GAFa dimer (Fig.
7, A and B), the former site corresponds to 16 residue seg-
ments in PDE6 (aa 59–74) and PDE6 (aa 57–72), which are
situated within the N-terminal 90-residue dimerization selec-
tivity regions. Chimeras His---5 and His---5 (Fig. 1)
have been constructed to test the possibility that these PDE6 
and  segments are responsible for the selectivity of PDE6
dimerization. Gel filtration tests (Fig. 6C) and sucrose density
centrifugation (not shown) revealed that, unlike other con-
structed rod PDE6 chimeras (Table I), His---5 was able to
form homodimers. His---5 and His---5 were then tested
for the ability to form heterodimers with FLAG---5 or myc-
--5. Consistent with the role of PDE6-59–74/PDE6-57–72
as determinants for PDE6 dimerization, His---5 failed to
dimerize with myc---5, whereas His---5 did not produce
dimers with FLAG---5 (not shown). Furthermore, although
His---5 was unable to dimerize with myc---5 (not shown),
His---5 displayed a gain of dimerization with FLAG---5
(Fig. 6D). The formation of FLAG---5His---5 dimers was
also confirmed using immunoprecipitation with anti-FLAG an-
tibodies followed by Western blotting with anti-His antibodies
(not shown).
DISCUSSION
The structural basis and functional role of PDE dimerization
are poorly understood because dimerization is not required for
catalytic function. The first molecular insights into PDE dimer-
ization have been revealed by the structure of the regulatory
domains of PDE2A (28). This crystal structure demonstrates
that the GAFa domain is responsible for the dimerization of
PDE2A. One apparent implication from the PDE2A structure
is that other GAF domain-containing PDEs, such as PDE5,
PDE6, PDE10, and PDE11 utilize GAF modules for dimeriza-
tion. Yet, it remains unclear how well the dimerization inter-
faces of PDE5 and PDE6 parallel that of PDE2. Although at a
relatively low resolution, electron microscopy imaging of PDE5
and PDE6 showed molecular shapes that are somewhat differ-
ent from the PDE2 structure (29). Furthermore, the electron
microscopy study indicates that, in addition to GAFa, GAFb
domains may contribute to the intersubunit interaction in
PDE5 and PDE6. Analysis of the dimerization interface of rod
PDE6 catalytic subunits permitted us to address two unre-
solved questions. What are the key structural determinants for
dimerization of PDE6, and are they similar to those identified
in the PDE2A structure? What are the selectivity determinants
of rod PDE6 heterodimerization? The heterodimerization of rod
PDE6  and  subunits is unique among known PDEs. It may
be critical in the forming of rod-specific photoresponses. How-
ever, a potential significance of PDE6 heterodimers and the
properties of individual subunits cannot be assessed in the
absence of  and  homodimers. Identification of the selec-
tivity determinants would be a first major step toward gener-
ation of the homodimeric species.
Our analysis of dimerization of chimeric PDE6/PDE5 pro-
teins using gel filtration, immunoprecipitation, and sucrose
gradient centrifugation demonstrated selective heterodimer-
ization between the GAF regions of PDE6 - and -subunits
with no significant homodimerization. This observation is in
accordance with the established heterodimeric nature of the
rod enzyme. Interestingly, the GAFa-GAFb region of PDE6,
but not PDE6, was capable of forming a dimer with the
GAFa-GAFb region of PDE6. Although dimerization of
PDE6 and PDE6 does not have physiological implications,
as the subunits are expressed in different types of photorecep-
tor cells, it may provide additional clues to understanding
PDE6 intersubunit interfaces. The patterns of dimerization (or
lack thereof) (Table I) show that the GAFa domains are the
major contributors to the dimer assembly of PDE. The finding
that the PDE6 GAFa domains, similar to the PDE2 GAFa
domains, are responsible for its dimerization suggests a com-
mon structural organization of the intersubunit interfaces of
the GAF domain-containing PDEs.
The subsequent identification of the PDE6 dimerization
selectivity determinants was carried out using chimeras carry-
ing complementing portions of the PDE6  and  GAFa do-
mains. The ability of His---5 to dimerize with FLAG---5
has implicated the N-terminal segment of the GAFa domains in
the exclusive PDE6 association. Further evidence was pro-
vided by the analysis of the chimeric PDEs, His---5 and
His---5, containing short replacements PDE6-57–72 and
PDE6-59–74 within the PDE6 and PDE6 GAF regions,
respectively. PDE6-57–72 and PDE6-59–74 correspond to a
region of PDE2GAFa, 1 helix-1/2 loop, that is involved in
the PDE2 dimer interface (28). Not only did the replacements
prevent heterodimerization between His---5 and myc---5,
and between His---5 and FLAG---5, but His---5
gained the ability for self-dimerization and heterodimerization
with FLAG---5. Dimerization of His---5 with FLAG---5
suggests that the lack of homodimerization of PDE6 is caused
by a defect in the interaction between the two PDE6-59–74
segments (Fig. 7D). However, homodimerization of His---5
coupled with the absence of association of His---5 with
myc---5 indicates that the lack of homodimerization of
PDE6 cannot be accounted for by the defective interaction
between the two PDE6-57–74 segments. Homology modeling
of the PDE6 GAFa dimer using the structure of PDE2GAFa
dimer as a template indicates that PDE6-57–72 may partici-
pate in two sets of interactions involving PDE6-59–74 and
PDE6-216–224 (Fig. 7, A–C). PDE6-216–224 resides at the
start of the helix connecting GAFa and GAFb. Table I shows
that no dimers had been formed that would entail the interac-
tion between PDE6-57–72 and the beginning of the connect-
ing helix from PDE6. Therefore, this structural constraint
appears to disallow homodimerization of PDE6 (Fig. 7D).
Additional negative dimerization determinants within the
GAFa domain of PDE6 cannot be ruled out. A significant
number of residues within PDE6-59–74/PDE6-57–72 and
PDE6-216–224/PDE6-214–222 are not conserved (Fig. 7B)
and may play a role in the selective assembly of PDE6.
The finding that the selectivity determinants of PDE6 di-
merization are confined to relatively short segments in the
GAFa domains supports the feasibility of generating mutant
PDE6  and  subunits capable of homodimerization. Mu-
tant homodimeric rod PDE6 expressed in transgenic ani-
mals would allow us to study the individual catalytic subunits
and elucidate the functional significance of rod PDE6
heterodimerization.
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